Thomas Wadden

Jul 24, 2024 | onlinelibrary.wiley.com | Michelle Cardel |Biomedical Informatics |Matthew Clark |Thomas Wadden

LETTER TO THE EDITOR Clarification of our response to “The importance of diversity in Obesity articles” Michelle Cardel,  Michelle Cardel WW International, Inc., New York, New York, USA Department of Health Outcomes and Biomedical Informatics, University of Florida College of Medicine, Gainesville, Florida, USASearch for more papers by this authorMatthew M. Clark,  Matthew M.

Feb 26, 2024 | nature.com | Thomas Wadden |Jamy Ard

Correction to: Nature Medicine https://doi.org/10.1038/s41591-023-02597-w, published online 15 October 2023. In the originally published version of this article, the labels in the Fig. 2 key for panels b and f (now shown as “Tirzepatide MTD” and “Placebo” for the inverted blue triangle and white box, respectively) were swapped. This error has been corrected in the HTML and PDF versions of the article.

Jan 11, 2024 | onlinelibrary.wiley.com | Robert F. Kushner |Thomas Wadden

LETTER TO THE EDITOR Response to “The safety of semaglutide in patients with depression and obesity” Robert F. Kushner,  Corresponding Author Robert F. Kushner Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA Correspondence Robert F. Kushner, Northwestern University Feinberg School of Medicine, Division of Endocrinology, 645 N. Michigan Ave., Suite 530, Chicago, IL 60611, USA. Email: [email protected] for more papers by this authorThomas A.

Oct 15, 2023 | nature.com | Thomas Wadden |Jamy Ard

AbstractThe effects of tirzepatide, a glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist, on weight reduction after successful intensive lifestyle intervention are unknown.